OncoGenomX ^None

OncoGenomX is a Swiss company that develops treatment guidance software, with its first product being PredictionStar. This software helps breast cancer doctors in determining the best treatment option for lasting metastasis prevention. The company uses AI-enabled treatment-tumor pairing, which has an 85% chance of determining the best treatment option, outperforming the competition's clinical decision offerings (55% chance). OncoGenomX's core competency is analyzing and interpreting digital clinical images, digital histology images, tumor and blood gene testing results to predict pharmacological weak points and provide tailor-made clinical decision guidance. The company's vision is to eliminate randomness and uncertainty from clinical decision support and cancer therapy decisions, while their mission is to become the best treatment guidance software and make durable metastasis prevention an option and a reality for all patients.